Novartis is going to have to wait a bit longer before it gets final word from the FDA on its marketing app for indacaterol, its experimental COPD therapy. The agency wants an extra three months to review data on the drug, which was rejected two years ago due to safety concerns. Analysts are keen to learn the fate of the drug, which Novartis wants approved in two doses. Experts, though, turned thumbs down on the higher dose, which could have an impact on QVA149, Novartis's blockbuster combo program. Story